BRPI0518255A2 - mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica - Google Patents

mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica

Info

Publication number
BRPI0518255A2
BRPI0518255A2 BRPI0518255-7A BRPI0518255A BRPI0518255A2 BR PI0518255 A2 BRPI0518255 A2 BR PI0518255A2 BR PI0518255 A BRPI0518255 A BR PI0518255A BR PI0518255 A2 BRPI0518255 A2 BR PI0518255A2
Authority
BR
Brazil
Prior art keywords
methods
nervous system
central nervous
system injury
reduce
Prior art date
Application number
BRPI0518255-7A
Other languages
English (en)
Inventor
Jerome B Zeldis
Herbert Faleck
Donald C Manning
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BRPI0518255A2 publication Critical patent/BRPI0518255A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODOS DE TRATAMENTO OU PREVENÇçO DE UMA LESçO DO SISTEMA NERVOSO CENTRAL, PARA REDUZIR OU EVITAR UM EFEITO ADVERSO, E, COMPOSIÇçO FARMACÊUTICA. Métodos de tratamento, prevenção e/ou controle de lesão/dano do sistema nervoso central e síndromes relacionadas são expostos. Métodos específicos abrangem a administração de um composto imunomodulatório isoladamente ou em combinação com um segundo agente ativo. Composições farmacêuticas, formas de dosagem unitárias únicas, e kits adequados para o uso em métodos da invenção são também expostos.
BRPI0518255-7A 2004-11-23 2005-11-18 mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica BRPI0518255A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63059804P 2004-11-23 2004-11-23
PCT/US2005/042330 WO2006058007A2 (en) 2004-11-23 2005-11-18 Jnk inhibitors for treatment of cns injury

Publications (1)

Publication Number Publication Date
BRPI0518255A2 true BRPI0518255A2 (pt) 2008-11-11

Family

ID=36061276

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518255-7A BRPI0518255A2 (pt) 2004-11-23 2005-11-18 mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica

Country Status (13)

Country Link
US (1) US20060122179A1 (pt)
EP (1) EP1827422A2 (pt)
JP (1) JP2008520730A (pt)
KR (1) KR20070086600A (pt)
CN (1) CN101102767A (pt)
AR (1) AR051968A1 (pt)
AU (1) AU2005309732A1 (pt)
BR (1) BRPI0518255A2 (pt)
CA (1) CA2588558A1 (pt)
IL (1) IL183329A0 (pt)
MX (1) MX2007006066A (pt)
WO (1) WO2006058007A2 (pt)
ZA (1) ZA200704889B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682803B2 (en) 2005-10-13 2010-03-23 Anthrogenesis Corporation Immunomodulation using placental stem cells
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CA2633980A1 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
EP2630959A1 (en) 2007-02-12 2013-08-28 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2009111264A2 (en) * 2008-02-29 2009-09-11 Alseres Pharmaceuticals, Inc. Systemic purine administration:modulating axonal outgrowth of central nervous system neurons
WO2010009139A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Imidazolyl pyrimidine inhibitor compounds
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
EP2331109B1 (en) 2008-08-22 2013-05-29 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2010039647A2 (en) * 2008-10-02 2010-04-08 Mayo Foundation For Medical Education And Research Selective inhibitors of c-jun n-terminal kinases
BRPI1010883A2 (pt) 2009-06-08 2018-07-10 Gilead Sciences Inc compostos inibidores da anilina cicloalquilcarbamato benzamida hdac.
CN102459159A (zh) 2009-06-08 2012-05-16 吉利德科学股份有限公司 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
CA2942687A1 (en) 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095415A (en) * 1958-05-30 1963-06-25 Ciba Ltd Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group
CH428043A (fr) * 1965-08-16 1967-01-15 Sandoz Ag Procédé de fabrication de colorants de dispersion isothiazolantroniques
US3541110A (en) * 1967-01-20 1970-11-17 American Home Prod Indazole-5-sulfonamides
JPS63184364A (ja) * 1987-01-27 1988-07-29 Toshiba Corp 半導体装置の製造方法
CN1137680C (zh) * 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU6870098A (en) * 1997-03-31 1998-10-22 Du Pont Merck Pharmaceutical Company, The Indazoles of cyclic ureas useful as hiv protease inhibitors
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US20030153560A1 (en) * 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
NZ517578A (en) * 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429609B2 (en) * 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain

Also Published As

Publication number Publication date
WO2006058007A3 (en) 2006-08-10
KR20070086600A (ko) 2007-08-27
ZA200704889B (en) 2008-09-25
EP1827422A2 (en) 2007-09-05
JP2008520730A (ja) 2008-06-19
AU2005309732A1 (en) 2006-06-01
IL183329A0 (en) 2008-04-13
MX2007006066A (es) 2007-07-11
AR051968A1 (es) 2007-02-21
WO2006058007A2 (en) 2006-06-01
US20060122179A1 (en) 2006-06-08
CN101102767A (zh) 2008-01-09
CA2588558A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
BRPI0518282A2 (pt) uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
NO20064584L (no) Tetrahydropyridoindolderivater
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
PA8580201A1 (es) Terapia de combinacion para enfermedades hiperproliferativas
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BRPI0518062A (pt) uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
BRPI0415971A (pt) método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]